Relapse Clinical Trials in Boston, Massachusetts
42 recruitingBoston, Massachusetts
Showing 1–20 of 42 trials
Recruiting
Phase 3
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Relapsed/Refractory Primary Central Nervous System Lymphoma
Ono Pharmaceutical Co., Ltd.132 enrolled8 locationsNCT07104032
Recruiting
Phase 1Phase 2
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078
Recruiting
Phase 1Phase 2
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb308 enrolled65 locationsNCT06090539
Recruiting
Phase 2
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Relapsed or Refractory Acute Myeloid Leukemia (AML)
H. Lee Moffitt Cancer Center and Research Institute52 enrolled2 locationsNCT06660368
Recruiting
Phase 1
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Acute Myeloid LeukemiaMyeloid SarcomaAcute Myeloid Leukemia, in Relapse+7 more
Kura Oncology, Inc.420 enrolled44 locationsNCT05735184
Recruiting
Phase 1
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Acute Lymphoblastic Leukemia, in RelapseAcute Leukemia of Ambiguous LineageAcute Lymphoblastic Leukemia With Failed Remission+8 more
Andrew E. Place, MD30 enrolled5 locationsNCT05292664
Recruiting
Phase 2
Outpatient Epcoritamab as 2L in NTE R/R DLBCL
Relapsed Large B-cell LymphomaRefractory Large B-cell Lymphoma
Massachusetts General Hospital30 enrolled2 locationsNCT06811272
Recruiting
Phase 1Phase 2
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Refractory CancerPrimary Central Nervous System LymphomaRecurrent Cancer+1 more
Dana-Farber Cancer Institute37 enrolled4 locationsNCT04421560
Recruiting
Phase 2
Epco, Zanu, Ritux for R/R FL or MZL
Non-Hodgkin LymphomaLymphomaFollicular Lymphoma+3 more
Reid Merryman, MD45 enrolled3 locationsNCT06563596
Recruiting
Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Relapsed or Refractory T Cell Lymphoma
Ono Pharmaceutical Co., Ltd.217 enrolled20 locationsNCT05079282
Recruiting
Phase 1Phase 2
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic LeukemiaLeukemiaRelapsed Leukemia+2 more
Jennifer R. Brown, MD, PhD64 enrolled1 locationNCT06644183
Recruiting
Phase 1
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome (MDS)Relapsed/Refractory Acute Myeloid Leukemia (AML)
Cullinan Therapeutics Inc.60 enrolled11 locationsNCT05143996
Recruiting
Not Applicable
Novel Digital Application for Patients With Acute Leukemia
Primary Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia
Massachusetts General Hospital200 enrolled3 locationsNCT06472128
Recruiting
Phase 1
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Relapsed/Refractory KMT2A-r Acute LeukemiaRelapsed/Refractory NUP98-r Acute LeukemiaRelapsed/Refractory NPM1-m Acute Leukemia
PedAL BCU, LLC20 enrolled20 locationsNCT06376162
Recruiting
Phase 2
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Relapsed Classic Hodgkin Lymphoma
City of Hope Medical Center31 enrolled5 locationsNCT04561206
Recruiting
Phase 1Phase 2
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Chronic Myelomonocytic LeukemiaMyelodysplastic Syndrome With Excess Blasts-2Leukemia, Myeloid, Acute+2 more
Aptose Biosciences Inc.240 enrolled34 locationsNCT03850574
Recruiting
Not Applicable
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Relapsed Adult AMLPrimary Refractory Acute Myeloid Leukemia
Massachusetts General Hospital2,300 enrolled20 locationsNCT05237258
Recruiting
Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Myelodysplastic SyndromesRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AML+1 more
Institut de Recherches Internationales Servier291 enrolled30 locationsNCT02074839
Recruiting
Phase 1
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Lymphoma, Non-HodgkinRefractory B-Cell Non-Hodgkin LymphomaRelapsed Non Hodgkin Lymphoma
Caribou Biosciences, Inc.72 enrolled38 locationsNCT04637763
Recruiting
Phase 1
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
Acute Myeloid Leukemia, in Relapse
Oryzon Genomics S.A.50 enrolled13 locationsNCT05546580